JP5112876B2 - 還元型グルタチオン経口投与のためのリポソーム処方物 - Google Patents

還元型グルタチオン経口投与のためのリポソーム処方物 Download PDF

Info

Publication number
JP5112876B2
JP5112876B2 JP2007539376A JP2007539376A JP5112876B2 JP 5112876 B2 JP5112876 B2 JP 5112876B2 JP 2007539376 A JP2007539376 A JP 2007539376A JP 2007539376 A JP2007539376 A JP 2007539376A JP 5112876 B2 JP5112876 B2 JP 5112876B2
Authority
JP
Japan
Prior art keywords
glutathione
disease
reduced
liposome
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007539376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518976A (ja
JP2008518976A5 (https=
Inventor
エフ． ギルフォード ティモシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2008518976A publication Critical patent/JP2008518976A/ja
Publication of JP2008518976A5 publication Critical patent/JP2008518976A5/ja
Application granted granted Critical
Publication of JP5112876B2 publication Critical patent/JP5112876B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007539376A 2004-11-07 2005-11-07 還元型グルタチオン経口投与のためのリポソーム処方物 Expired - Lifetime JP5112876B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US52278504P 2004-11-07 2004-11-07
US60/522,785 2004-11-07
US59499605P 2005-05-25 2005-05-25
US60/594,996 2005-05-25
US59704105P 2005-11-06 2005-11-06
US60/597,041 2005-11-06
PCT/US2005/040308 WO2006060120A2 (en) 2004-11-07 2005-11-07 Liposomal formulation for oral administration of glutathione (reduced)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012005488A Division JP5571706B2 (ja) 2004-11-07 2012-01-13 還元型グルタチオン経口投与のためのリポソーム処方物

Publications (3)

Publication Number Publication Date
JP2008518976A JP2008518976A (ja) 2008-06-05
JP2008518976A5 JP2008518976A5 (https=) 2012-09-13
JP5112876B2 true JP5112876B2 (ja) 2013-01-09

Family

ID=36565495

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007539376A Expired - Lifetime JP5112876B2 (ja) 2004-11-07 2005-11-07 還元型グルタチオン経口投与のためのリポソーム処方物
JP2012005488A Expired - Fee Related JP5571706B2 (ja) 2004-11-07 2012-01-13 還元型グルタチオン経口投与のためのリポソーム処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012005488A Expired - Fee Related JP5571706B2 (ja) 2004-11-07 2012-01-13 還元型グルタチオン経口投与のためのリポソーム処方物

Country Status (7)

Country Link
EP (1) EP1817006B1 (https=)
JP (2) JP5112876B2 (https=)
CA (1) CA2628777C (https=)
ES (1) ES2395555T3 (https=)
IL (1) IL182950A (https=)
PL (1) PL1817006T3 (https=)
WO (1) WO2006060120A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868572A4 (en) * 2005-03-29 2011-03-09 F Timothy Guilford ADMINISTRATION OF GLUTATHION (REDUCED) ON THE INTRAVENOUS WAY OR CAPSULATED IN A LIPOSOME FOR THE TREATMENT OF TNF ALPHA EFFECTS AND FLUID VIRAL SYMPTOMS
WO2011036557A1 (en) * 2009-09-22 2011-03-31 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
WO2011082283A2 (en) * 2009-12-30 2011-07-07 Guilford F Timothy Management of myoclonus with oral liposomal reduced glutathione
WO2012094033A1 (en) 2011-01-05 2012-07-12 Livon Laboratories Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
WO2013103840A1 (en) * 2012-01-05 2013-07-11 Guilford Frederick Timothy Anti-cancer composition and method utilizing 3-bp and liposomal reduced glutathione
WO2013109421A1 (en) * 2012-01-05 2013-07-25 Guilford Frederick Timothy Liposomally encapsulated reduced glutathione for management of cancer and disruption of cancer energy cycles
WO2014070769A1 (en) 2012-10-29 2014-05-08 The University Of North Carolina At Chapel Hill Methods and compositions for treating mucosal tissue disorders
WO2014126594A1 (en) * 2013-02-15 2014-08-21 Guilford Frederick Timothy Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
TWI589308B (zh) 2014-03-25 2017-07-01 林信湧 一種用於治療帕金森氏症之吸入式醫藥組成物及其備製方法
AU2017362500B2 (en) 2016-11-17 2024-09-26 Renovion, Inc. Treatment of Respiratory Tract Diseases and Infections with Ascorbic Acid Compositions
BR112020009910A2 (pt) 2017-11-17 2020-11-03 Renovion, Inc. composições de ácido ascórbico estáveis e métodos de usar as mesmas
KR102171719B1 (ko) 2018-11-14 2020-10-29 충남대학교산학협력단 경구투여용 글루타치온 함유 프로리포좀, 이를 포함하는 약제학적 조성물 및 이의 제조방법
KR20240131358A (ko) 2022-01-04 2024-08-30 레노비온, 아이엔씨. 글루타치온 염을 포함하는 수용액

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746921A (en) * 1980-09-02 1982-03-17 Green Cross Corp:The Oral preparation of human blood coagulation factor
FR2609393A1 (fr) * 1988-02-23 1988-07-15 Serobiologiques Lab Sa Composition notamment utile comme matiere de base pour la preparation de compositions pharmaceutiques, notamment dermatologiques et/ou cosmetiques comprenant une substance azotee, notamment aminoacides, oligo- ou polypeptides, proteines, et leurs derives, et composition pharmaceutique ou cosmetique ainsi preparee.
US5238683A (en) * 1989-11-24 1993-08-24 The United States Of America As Represented By The Department Of Health And Human Services Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
JP3272736B2 (ja) * 1991-01-31 2002-04-08 協和醗酵工業株式会社 リポソーム製剤
IT1257697B (it) * 1992-04-24 1996-02-01 Lifegroup Spa N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico.
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
JPH0859503A (ja) * 1994-08-26 1996-03-05 Teijin Ltd ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤
US5500232A (en) * 1994-10-06 1996-03-19 Bristol-Myers Squibb Company Calcium fortified beverages
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
GB9620504D0 (en) * 1996-10-02 1996-11-20 Boehringer Ingelheim Ltd Compositions
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
DE69739663D1 (de) * 1996-12-31 2009-12-31 Antioxidant Pharmaceuticals Co Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
US6756056B2 (en) * 1997-04-08 2004-06-29 Alan A. Rubin Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
US6470894B2 (en) * 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
US5829449A (en) * 1997-09-19 1998-11-03 Thione International, Inc. Smoking products containing antioxidants
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
JP3989803B2 (ja) * 2002-09-18 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 食品腐敗菌の増殖抑制方法

Also Published As

Publication number Publication date
EP1817006A4 (en) 2009-12-02
JP2012102138A (ja) 2012-05-31
JP2008518976A (ja) 2008-06-05
ES2395555T3 (es) 2013-02-13
WO2006060120A3 (en) 2006-09-14
CA2628777C (en) 2016-09-13
CA2628777A1 (en) 2006-06-08
JP5571706B2 (ja) 2014-08-13
EP1817006B1 (en) 2012-09-05
PL1817006T3 (pl) 2013-03-29
WO2006060120A2 (en) 2006-06-08
EP1817006A2 (en) 2007-08-15
IL182950A (en) 2013-10-31
IL182950A0 (en) 2007-08-19

Similar Documents

Publication Publication Date Title
JP5571706B2 (ja) 還元型グルタチオン経口投与のためのリポソーム処方物
US8252325B2 (en) Liposome-encapsulated glutathione for oral administration
TW201249477A (en) Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
KR102375232B1 (ko) 비강내 에피네프린 제제 및 질환의 치료 방법
JP2012533559A (ja) アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法
WO2022272176A1 (en) Psilocybin analogs for treating psychological disorders
EP2956131B1 (en) Treatment of klebsiella pneumoniae with liposomally formulated glutathione
JP5529165B2 (ja) 脂質低下薬を経口腔粘膜投与する処方物（ｆｏｒｍｕｌａｔｉｏｎ）
WO2014126594A1 (en) Treatment of evolving bacterial resistance diseases including klebsiella pneumoniae with liposomally formulated glutathione
US20240335401A1 (en) Substituted phenethylamine for treating inflammation and psychological disorders
RU2189813C1 (ru) Лекарственное средство антигипоксического действия
US20050191341A1 (en) Liposomal composition comprising L-theanine
US20100173014A1 (en) Methods of making and using nano scale particles
JPS61134313A (ja) アルデヒドの毒性抑制剤
CA3214543A1 (en) Bioavailable mixture providing safe, broad-spectrum, antipathogenic, health, fitness, neurological, and homeostatic benefits
US20160317452A1 (en) Methods of Making and Using Nano Scale Particles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110713

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120629

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120924

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121011

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151019

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5112876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term